GLP-1 Mediating DPP-4 Inhibition in Type 2 Diabetes

NCT02639130 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

67

Enrollment

OTHER

Sponsor class

Conditions

Type 2 Diabetes

Interventions

DRUG: Exendin [9-39]
DRUG: Placebo

Sponsor

Diabeteszentrum Bad Lauterberg im Harz